Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥3,740.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)1.36M
Market Cap
¥211.67B
Enterprise Value¥172.97B
Total Cash (Recent Filing)¥17.16B
Total Debt (Recent Filing)¥5.07B
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 13, 2026EPS Estimate
27.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-102.58
Shares Outstanding65,851,105
10 Day Avg. Volume1,788,340
30 Day Avg. Volume1,356,033
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.29
Revenue Forecast (FY)¥40.18B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsA gross margin near 75% indicates the company retains substantial value after direct costs, providing a strong foundation for future operating improvement. If revenue stabilizes and expenses are controlled, this margin profile can support reinvestment and eventual earnings recovery.
Manageable LeverageLow debt relative to equity reduces balance-sheet pressure and gives the company greater flexibility to fund operations, absorb weaker results, or pursue growth. This provides a more durable financial cushion than a highly leveraged structure during periods of earnings volatility.
Established Revenue BaseThe company has demonstrated an ability to expand its revenue base, including strong growth in earlier periods and reported positive growth overall. That established demand base can support recovery if management restores profitability and reverses the more recent slowdown.
Bears Say
Recurring LossesThe return to sizable operating and net losses shows that strong gross margins are not currently converting into sustainable earnings. Continued losses can weaken retained capital, restrict investment choices, and make future performance dependent on a successful operating turnaround.
Persistent Cash BurnNegative operating and free cash flow indicate that the business is not currently funding itself through operations. Even with manageable leverage, ongoing cash burn can increase reliance on external funding and reduce flexibility if weak profitability persists.
Volatile Financial PerformanceThe sharp swing from strong profits to renewed losses, alongside deteriorating revenue momentum, indicates limited earnings stability. This volatility makes planning and capital allocation harder and raises the risk that high gross margins will not translate into dependable shareholder returns.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥3740.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥211.67B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 14 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Aug 14, 2026. The company reported ¥2.54 earnings per share for the quarter, beating the consensus estimate of -¥61.64 by ¥64.18.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 27.3.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,851,105 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of ¥2.54 in its last earnings report, beating expectations of -¥61.64. Following the earnings report the stock price went up 1.312%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.